Novo Nordisk Undeterred By Regulatory Hurdles For Diabetes Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Potential regulatory hurdles for type 2 diabetes drugs -- namely the threat that FDA could require large cardiovascular outcomes studies -- has made the therapeutic area look far less attractive to drug makers than it did a year ago.